Physician profile
Robert A Wild
NPI 1316915671
$2,863.51
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,920 · 2020: $500 · 2022: $76.63 · 2023: $130 · 2024: $237.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $244 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $122.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $244.26 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $122.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,639.17 | 2019-2023 | |
| Regeneron Healthcare Solutions, INC. | $191.22 | 2022-2024 | Evkeeza |
| Abbvie INC. | $128.49 | 2019 | |
| Sanofi-Aventis U.S. LLC | $124.99 | 2019 | |
| Corcept Therapeutics | $124.37 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $123.10 | 2019 | |
| Medicure Pharma INC. | $122.34 | 2024 | Zypitamag |
| Novo Nordisk INC | $104.54 | 2019 | |
| Kaneka Medical America LLC | $104.09 | 2019 | |
| Therapeuticsmd, INC. | $93.97 | 2019 | |
| Lilly USA, LLC | $91.37 | 2019 | |
| Axonics, INC. | $15.86 | 2023 | Axonics |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Wild listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.